EFFICACY OF BRENTUXIMAB VEDOTIN AND OTHER TREATMENTS IN PATIENTS WITH RELAPSED OR REFRACTORY (RR) SYSTEMIC ANAPLASTIC LARGE-CELL LYMPHOMA (SALCL): A SYSTEMATIC REVIEW

被引：0
|
作者：
Hamashima, C. [1 ]
Ogoshi, K. [2 ]
Okamoto, M. [3 ]
Shabana, M. [4 ]
Kishimoto, T. [3 ]
Fukao, A. [5 ]
机构：
[1] Natl Canc Ctr Japan, Tokyo, Japan
[2] Niigata Canc Ctr Hosp, Niigata, Japan
[3] Tottori Univ, Yonago, Tottori, Japan
[4] San in Rosai Hosp, Yonago, Tottori, Japan
[5] Yamagata Univ, Yamagata 990, Japan
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 07期
关键词：
D O I：
10.1016/j.jval.2013.08.417
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A395 / A395
页数：1
相关论文
共 50 条
  • [1] Brentuximab vedotin: treatment role for relapsed refractory systemic anaplastic large-cell lymphoma
    Lai, Chao-Ming
    Horowitz, Sandra
    EXPERT REVIEW OF HEMATOLOGY, 2013, 6 (04) : 361 - 373
  • [2] Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma
    Ishizawa, Kenichi
    Yanai, Tomoko
    ADVANCES IN THERAPY, 2019, 36 (10) : 2679 - 2696
  • [3] Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma
    Kenichi Ishizawa
    Tomoko Yanai
    Advances in Therapy, 2019, 36 : 2679 - 2696
  • [4] Cost-effectiveness of brentuximab vedotin for relapsed or refractory systemic anaplastic large-cell lymphoma in China
    Liu, Jia
    Zheng, Lei
    Chuang, Ling-Hsiang
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 99 - 107
  • [5] Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature
    Zinzani, P. L.
    Sasse, S.
    Radford, J.
    Shonukan, O.
    Bonthapally, V.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2015, 95 (03) : 359 - 369
  • [6] BRENTUXIMAB VEDOTIN DESENSITIZATION IN A FEMALE WITH RELAPSED, REFRACTORY, ANAPLASTIC LARGE-CELL LYMPHOMA (ALCL)
    Qamar, N.
    Cho, S.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2012, 109 (05) : A68 - A68
  • [7] Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)
    Forero-Torres, Andres
    Berryman, R. Brian
    Advani, Ranjana H.
    Bartlett, Nancy L.
    Chen, Robert W.
    Fanale, Michelle A.
    Gopal, Ajay K.
    O'Connor, Owen A.
    Olshefski, Randal
    Smith, Scott E.
    Grove, Laurie E.
    Matous, Jeffrey
    BLOOD, 2011, 118 (21) : 1585 - 1586
  • [8] Retreatment with brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study
    Fukuhara, Noriko
    Yamamoto, Go
    Tsujimura, Hideki
    Chou, Takaaki
    Shibayama, Hirohiko
    Yanai, Tomoko
    Shibuya, Kazunori
    Izutsu, Koji
    LEUKEMIA & LYMPHOMA, 2020, 61 (01) : 176 - 180
  • [9] Phase I/II study of brentuximab vedotin in pediatric patients (pts) with relapsed or refractory (RR) Hodgkin lymphoma (HL) or systemic anaplastic large-cell lymphoma (sALCL): Interim phase (ph) I safety data
    Neville, Kathleen
    Gore, Lia
    Mauz-Koerholz, Christine
    Rosolen, Angelo
    Landman-Parker, Judith
    de Toledo, Jose Sanchez
    Beishuizen, Auke
    Franklin, Anna Rachel Keating
    Fasanmade, Adedigbo
    Wang, Jingyuan
    Huebner, Dirk
    Locatelli, Franco
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] Relapsed or refractory anaplastic large cell lymphoma: Brentuximab vedotin of course!
    Paillassa, Jerome
    HEMATOLOGIE, 2018, 24 (01): : 19 - 21
12345